It has been known for many years that abnormally enhanced fibrinolysis is responsible for some of the haemorrhagic problems associated with hepatic cirrhosis.' 2 In 1964 Fletcher et a13 showed that the in vivo clearance rate for plasma plasminogen activator after nicotinic acid injection was four times slower in cirrhotic patients than in normal controls. They suggested that abnormal fibrinolysis in cirrhosis may be due to failure of hepatic clearance mechanisms for plasminogen activator.
The primary plasma inhibitor of plasmin a2 antiplasmin is decreased in liver disease. 4 Histidine rich glycoprotein, which is an inhibitor of fibrinolysis,5 is similarly affected.6' These observations provide additional or alternative explanations for the fibrinolytic activity seen in hepatic cirrhosis.
The technique of sodium dodecyl sulphatepolyacrylamide gel electrophoresis (SDS-PAGE), followed by zymography on fibrin agarose layers," has been applied to the analysis of plasma samples for plasminogen activators.' Using this approach, together with other methods, we have studied the fibrinolytic system in a group of patients with alcoholic cirrhosis. The aims of the study were: (a) to examine the nature of plasminogen activators responsible for increased fibrinolytic activity in cirrhosis; and (b) to immunoelectrophoresis against antiserum to a2 antiplasmin was performed as described previously. '3 14 In some studies purified human plasminogen"' was incorporated into the agarose gel in the first dimension at a final concentration of 041 mg/ml to distinguish between plasminogen binding and non-binding forms of a2-antiplasmin. '6 The overall fibrinolytic activity of plasma was assessed by assay of unfractionated plasma on plasminogen replete fibrin plates.'4 " The euglobulin clot lysis time was measured as described previously."' Plasma plasminogen activators were fractionated on lysine-Sepharose, essentially as described by Radcliffe and Heinze.'9 Plasma samples (2ml) were loaded on to columns (0-8 x 3-5 cm), equilibrated with 50mM Tris, 1mM benzamidine, 1mM edetic acid pH7*5, and eluted with 1*5M NaCl followed by Plasminogen activators in alcoholic cirrhosis 0-2M e-aminocaproic acid, each dissolved in this buffer.
SDS-PAGE with zymography on fibrin agarose layers was by the method of Granelli-Piperno and Reich.8 Samples (10,ul) were prepared for SDS-PAGE by incubation with 10,l of 8M urea, 4% sodium dodecyl sulphate, 40mM iodoacetamide, 0-2M Tris pH8.0, for 30 min at 37°C and then made 10% with respect to glycerol. They were applied to a Laemmli20 gel (separating and stacking gels were 10% and 3% acrylamide respectively; gel was 180 x 200 x 1-2mm) and run at 20mA for 3.5 h. The gel was washed for 1 h in 1 litre of 2 5 % aqueous Triton X-100 with constarnt agitation and rinsed repeatedly with distilled water before applying to a 1-3mm thick fibrin agarose layer (Kabi fibrinogen, either containing plasminogen or depleted of plasminogen on lysine-Sepharose'5 2mg/ml; thrombin 0 06U/ nml,-17-5mM NaCl, 60mM Tris pH7-8, 0-8% agarose; final concentrations). After incubation overnight at 37°C the polyacrylamide gel was removed and the fibrin agarose layer, with activity apparent as bands of lysis, was photographed. When No complex of a2-antiplasmin was found. This contrasts with other conditions with comparably low a2-antiplasmin concentrations and similarly enhanced activity on fibrin plates, such as disseminated intravascular coagulation or primary hyperfibrinolysis (Fig. 1) .'3 1148 Crossed immunoelectrophoresis of a2-antiplasmin with plasminogen incorporated into the gel was normal (Fig. 2) , indicating a normal ratio of plasminogen binding and nonbinding forms.
Plasma samples were analysed on SDS-PAGE, followed by zymography. Fig. 3 shows the pattern of plasminogen activator activities; the patients' plasma samples showed increased plasminogen activator activities compared with normal plasma. The major bands of activity in cirrhotic plasma had molecular weights of about 50 and 95K. These bands could be inhibited by antisera to tissue type plasminogen activator or to urokinase (Fig. 4) was fractionated on lysine-Sepharose and the fractions assayed for plasminogen activator activity on fibrin plates. Assay by this method showed a single peak of activity, eluted by 1-5M NaCl, when patients' plasma was fractionated (Fig. 5) . No activity was seen by this method when normal plasma was fractionated. The fractions were also analysed by SDS-PAGE and zymography. The fractions from normal plasma contained 95K tissue type plasminogen activator in both the unbound peak and the 1-5M NaCl eluate (data not shown). The unbound fractions from patients' plasma contained both 50K urokinase related activity and tissue type plasminogen activator related activity of molecular weight 95K and lower (Fig. 5) . The activity eluted with 1-5M NaCl consisted mainly of 95K and 65K material with a minor band of about 160K. All these bands were related to tissue type plasminogen LI', In this study the question of increased plasma concentrations of plasminogen activator in liver disease was re-examined in the light of current knowledge of the various types of plasminogen activator which exist in blood. The high plasma concentrations of plasminogen activator, noted previously in hepatic cirrhosis,3 23 were confirmed, and the study was extended to examine the nature of the activator(s) present. The earlier studies measured overall concentrations of plasminogen activator and did not discriminate between different types. Additionally, the methods used previously measured activator in fractions of plasma (prepared specifically to exclude proteins such as protease inhibitors from the assay systems) rather than in whole plasma; this may have excluded material from study. In this study the use of SDS-PAGE with zymography had the advantage of allowing examination of whole plasma. No material was excluded from the system and the different activators were separated from one another and from potential inhibitor proteins in the system itself, allowing demonstration of each plasminogen activator present. The activators in the plasma of the patients studied could be classified as tissue type plasminogen activator or urokinase type plasminogen activator on the basis of inhibition by specific antiserum to these activators. It is clear that both types of plasminogen activator are considerably raised in these patients. Another recent study has shown an increase in tissue type plasminogen activator,24 using different techniques, but this is to our knowledge the first demonstration of increased urokinase type plasminogen activator in hepatic cirrhosis.
Separation of plasma plasminogen activators on lysine-Sepharose, followed by assay of the column fractions on fibrin plates, indicates that all the activity of patients' plasma was bound to lysineSepharose and could be eluted with 1-5M NaCl. This is in agreement with Radcliffe and Heinze, '9 who assayed fractions from post-exercise plasma on fibrin plates and found all the activity in the 1-5M NaCl wash. When the fractions from cirrhotic plasma were analysed by SDS-PAGE, followed by zymography, activity was apparent in the unbound fractions as well. The unbound activity included 
